XML 55 R16.htm IDEA: XBRL DOCUMENT

Convertible Preferred Shares	12 Months Ended
Convertible Preferred Shares	Dec. 31, 2019
Temporary Equity Disclosure [Abstract]
Convertible Preferred Shares	Convertible Preferred Shares Prior to the completion of its IPO in October 2017, the Company had outstanding Series A, Series B-1, Series B-2 and Series C convertible preferred shares. The Conversion included the exchange of all outstanding Series A, Series B and Series C preferred shares of Deciphera Pharmaceuticals, LLC for an aggregate of 24,425,190 shares of common stock of Deciphera Pharmaceuticals, Inc. For additional information on the IPO and conversion, please read Note 1, Nature of the Business and Basis of Presentation, to these consolidated financial statements. In May 2017, the Company entered into a Series C preferred shares purchase agreement, pursuant to which the Company sold 690,333 Series C Shares at a price of $75.76 per share for proceeds of $51.9 million, net of issuance costs of $0.4 million.